Table 8 Patient value conferred by drug classes across medicine [16, 37]
Drug class | Indication | # of drugs | Patient value gain (%) |
|---|---|---|---|
Histamine H-1 receptor antagonists, oral | Seasonal allergy | 10 | 4–7 |
Histamine H-1 receptor antagonists, topical ocular | Allergy, ocular | 6 | 0.1–9.9 |
SSRI drugs | Depression, major | 5 | 20–23 |
Anti-depressants, non-SSRI | Depression, major | 6 | 21–32 |
cGMP-specific phosphodi-esterase inhibitors | Erectile dysfunction | 3 | 2.7–2.9 |
Proton pump inhibitors | Acute erosive esophagitis | 5 | 13–26 |
Proton pump inhibitors | Gastroesophageal reflux | 5 | 8–14 |
Proton pump inhibitors | Zollinger-Ellison Syndrome | 5 | 29–38 |
Histamine H-2 receptor antagonists | Acute erosive esophagitis | 4 | 5–11 |
Histamine H-2 receptor antagonists | Gastroesophageal reflux | 4 | 3–7 |
B-blockers, topical | Glaucoma | 3 | 16–19 |
Statins | Hyperlipidemia | 6 | 3–5 |
Diuretics | Hypertension, systemic arterial | 5 | 7.7–9.4 |
ACE inhibitors | Hypertension, systemic arterial | 9 | 6.5–9.1 |
B-blockers, oral | Hypertension, systemic arterial | 7 | 6.3–9.1 |
Hypnotics | Insomnia | 7 | 1.2–8.8 |
Ranibizumab, combined eye model | Neovascular age-related macular degeneration, current study | 1 | 16.3 |
Bisphosphonates | Osteoporosis | 3 | 0.8–1.1 |
α1-adrenergic blockers | Prostatic hyperplasia | 3 | 0.6–1.4 |